Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
350
¥ millionWording
Conditional
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 2025 年 5 月 30 日Net Sales10,350→10,700million
+3.4%
Operating profit300→600million
+100.0%
Ordinary income360→650million
+80.6%
Profit attributable to owners of the parent250→600million
+140.0%
Net income per share30.93→73.73yen and sen
+138.4%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
ファインケミカル事業における医薬分野での一時的な大口需要への対応およびヨウ素関連製品等の高収益製品の販売増に加え、全事業の一部製品における販売単価の見直し。
Previous-period results売上高9,304百万円、営業利益△342百万円、経常利益△275百万円、親会社株主に帰属する当期純利益△895百万円、１株当たり当期純利益△110.77円 銭（2025年3月期）
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥10,350 million → ¥10,700 million（+3.4%） |
| Operating profit | ¥300 million → ¥600 million（+100.0%） |
| Ordinary income | ¥360 million → ¥650 million（+80.6%） |
| Profit attributable to owners of the parent | ¥250 million → ¥600 million（+140.0%） |
| Net income per share | 30.93 yen and sen → 73.73 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 2025 年 5 月 30 日 |
| Previous-period results | 売上高9,304百万円、営業利益△342百万円、経常利益△275百万円、親会社株主に帰属する当期純利益△895百万円、１株当たり当期純利益△110.77円 銭（2025年3月期） |
| Reason for the revision | ファインケミカル事業における医薬分野での一時的な大口需要への対応およびヨウ素関連製品等の高収益製品の販売増に加え、全事業の一部製品における販売単価の見直し。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ファインケミカル事業の医薬分野における一時的な大口需要への対応、ヨウ素関連製品など高収益製品の販売増、全事業の一部製品における販売単価の見直し。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.